Cosmo Feilding Mellen

Private psychedelics medicine company Beckley Psytech Ltd. has acquired 100% of clinical-stage life sciences company Eleusis Therapeutics Ltd., entitling the former to full developmental and commercial rights of the latter’s assets.  Eleusis CEO Shlomi Raz will become Beckley’...

Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund. The oversubscribed fund is positioned to have a transformative impact on the field of mental health by funding a diverse portfolio...

Beckley Psytech Closes $80 Million Series B Beckley Psytech announced the closing of a £58 million ($80 million) Series B raise, which will be used to further finance the company’s psilocybin and 5-MeO-DMT research into neuropsychiatric disorders. The financing was upsized from an...

5-MeO-DMT is a potent and fast-acting psychedelic, which is naturally produced by the Sonoran Desert toad as well as some species of plants. Its short duration –from 20 minutes to one hour– is giving hope to researchers and executives in the psychedelics space who are seeking ...